Oncometabolism (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Oncometabolism" in English language version.

refsWebsite

Global rank English rank

72nih.gov

4^th place

46doi.org

2^nd place

11semanticscholar.org

11^th place

8^th place

4harvard.edu

18^th place

17^th place

2handle.net

102^nd place

76^th place

1ebi.ac.uk

5,849^th place

7,886^th place

1worldcat.org

5^th place

doi.org

Urbano AM (January 2021). "Otto Warburg: The journey towards the seminal discovery of tumor cell bioenergetic reprogramming". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1867 (1): 165965. doi:10.1016/j.bbadis.2020.165965. PMID 32949769. S2CID 221807074.
Oliveira PJ, Urbano AM (February 2021). ""Oncometabolism: The switchboard of cancer - An editorial"". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1867 (2): 166031. doi:10.1016/j.bbadis.2020.166031. PMID 33310398. S2CID 229175329.
Cooper CS (1990). "The Role of Oncogene Activation in Chemical Carcinogenesis". Chemical Carcinogenesis and Mutagenesis II. Handbook of Experimental Pharmacology. Vol. 94. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 319–352. doi:10.1007/978-3-642-74778-6_12. ISBN 978-3-642-74780-9.
Dando I, Pozza ED, Ambrosini G, Torrens-Mas M, Butera G, Mullappilly N, et al. (August 2019). "Oncometabolites in cancer aggressiveness and tumour repopulation". Biological Reviews of the Cambridge Philosophical Society. 94 (4): 1530–1546. doi:10.1111/brv.12513. PMID 30972955. S2CID 108294182.
Biswas SK (September 2015). "Metabolic Reprogramming of Immune Cells in Cancer Progression". Immunity. 43 (3): 435–449. doi:10.1016/j.immuni.2015.09.001. PMID 26377897.
Vaupel P, Schmidberger H, Mayer A (July 2019). "The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression". International Journal of Radiation Biology. 95 (7): 912–919. doi:10.1080/09553002.2019.1589653. PMID 30822194. S2CID 73502809.
Pascale RM, Calvisi DF, Simile MM, Feo CF, Feo F (September 2020). "The Warburg Effect 97 Years after Its Discovery". Cancers. 12 (10): 2819. doi:10.3390/cancers12102819. PMC 7599761. PMID 33008042.
Potter M, Newport E, Morten KJ (October 2016). "The Warburg effect: 80 years on". Biochemical Society Transactions. 44 (5): 1499–1505. doi:10.1042/bst20160094. PMC 5095922. PMID 27911732.
Lunt SY, Vander Heiden MG (2011-11-10). "Aerobic glycolysis: meeting the metabolic requirements of cell proliferation". Annual Review of Cell and Developmental Biology. 27 (1): 441–464. doi:10.1146/annurev-cellbio-092910-154237. hdl:1721.1/78654. PMID 21985671.
Van Dang C (October 2015). "Abstract IA05: Targeting MYC-mediated cancer metabolism". Molecular Cancer Research. 13 (10_Supplement). American Association for Cancer Research: IA05. doi:10.1158/1557-3125.myc15-ia05.
DeBerardinis RJ, Chandel NS (May 2016). "Fundamentals of cancer metabolism". Science Advances. 2 (5): e1600200. Bibcode:2016SciA....2E0200D. doi:10.1126/sciadv.1600200. PMC 4928883. PMID 27386546.
Wishart DS (July 2016). "Emerging applications of metabolomics in drug discovery and precision medicine". Nature Reviews. Drug Discovery. 15 (7): 473–484. doi:10.1038/nrd.2016.32. PMID 26965202. S2CID 5265996.
Gupta S, Chawla K (August 2013). "Oncometabolomics in cancer research". Expert Review of Proteomics. 10 (4): 325–336. doi:10.1586/14789450.2013.828947. PMID 23992416. S2CID 19476401.
Collins RR, Patel K, Putnam WC, Kapur P, Rakheja D (December 2017). "Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory". Clinical Chemistry. 63 (12): 1812–1820. doi:10.1373/clinchem.2016.267666. PMID 29038145.
Yang M, Soga T, Pollard PJ, Adam J (2012). "The emerging role of fumarate as an oncometabolite". Frontiers in Oncology. 2: 85. doi:10.3389/fonc.2012.00085. PMC 3408580. PMID 22866264.
Garber K (July 2010). "Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia". Journal of the National Cancer Institute. 102 (13): 926–928. doi:10.1093/jnci/djq262. PMID 20576929.
Khatami F, Aghamir SM, Tavangar SM (September 2019). "Oncometabolites: A new insight for oncology". Molecular Genetics & Genomic Medicine. 7 (9): e873. doi:10.1002/mgg3.873. PMC 6732276. PMID 31321921.
Salamanca-Cardona L, Shah H, Poot AJ, Correa FM, Di Gialleonardo V, Lui H, et al. (December 2017). "In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors". Cell Metabolism. 26 (6): 830–841.e3. doi:10.1016/j.cmet.2017.10.001. PMC 5718944. PMID 29056515.
Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, et al. (May 2013). "The role of sarcosine metabolism in prostate cancer progression". Neoplasia. 15 (5): 491–501. doi:10.1593/neo.13314. PMC 3638352. PMID 23633921.
Rodrigo MA, Strmiska V, Horackova E, Buchtelova H, Michalek P, Stiborova M, et al. (February 2018). "Sarcosine influences apoptosis and growth of prostate cells via cell-type specific regulation of distinct sets of genes". The Prostate. 78 (2): 104–112. doi:10.1002/pros.23450. PMID 29105933. S2CID 3015270.
Chen M, Yang MH, Chang MM, Tyan YC, Chen YA (September 2019). "Tumor suppressor gene glycine N-methyltransferase and its potential in liver disorders and hepatocellular carcinoma". Toxicology and Applied Pharmacology. 378: 114607. Bibcode:2019ToxAP.37814607C. doi:10.1016/j.taap.2019.114607. PMID 31170416. S2CID 174817577.
Heinzman Z, Schmidt C, Sliwinski MK, Goonesekere NC (March 2021). "The Case for GNMT as a Biomarker and a Therapeutic Target in Pancreatic Cancer". Pharmaceuticals. 14 (3): 209. doi:10.3390/ph14030209. PMC 7998508. PMID 33802396.
Chiu M, Taurino G, Bianchi MG, Kilberg MS, Bussolati O (2020-01-09). "Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia". Frontiers in Oncology. 9: 1480. doi:10.3389/fonc.2019.01480. PMC 6962308. PMID 31998641.
Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y (December 2018). "Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy". Cancer Medicine. 7 (12): 6124–6136. doi:10.1002/cam4.1820. PMC 6308051. PMID 30403008.
Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ (January 2016). "The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor". Brain Pathology. 26 (1): 3–17. doi:10.1111/bpa.12299. PMC 8029296. PMID 26269128.
Yang M, Soga T, Pollard PJ (September 2013). "Oncometabolites: linking altered metabolism with cancer". The Journal of Clinical Investigation. 123 (9): 3652–3658. doi:10.1172/jci67228. PMC 3754247. PMID 23999438.
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. (February 2012). "IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype". Nature. 483 (7390): 479–483. Bibcode:2012Natur.483..479T. doi:10.1038/nature10866. PMC 3351699. PMID 22343889.
Jones PA, Baylin SB (February 2007). "The epigenomics of cancer". Cell. 128 (4): 683–692. doi:10.1016/j.cell.2007.01.029. PMC 3894624. PMID 17320506.
Letouzé E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, et al. (June 2013). "SDH mutations establish a hypermethylator phenotype in paraganglioma". Cancer Cell. 23 (6): 739–752. doi:10.1016/j.ccr.2013.04.018. PMID 23707781.
Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. (January 2012). "2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas". Nature Medicine. 18 (4): 624–629. doi:10.1038/nm.2682. PMC 3615719. PMID 22281806.
Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. (May 2013). "Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation". Science. 340 (6132): 622–626. Bibcode:2013Sci...340..622W. doi:10.1126/science.1234769. PMID 23558173. S2CID 9292787.
Ye D, Guan KL, Xiong Y (February 2018). "Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates". Trends in Cancer. 4 (2): 151–165. doi:10.1016/j.trecan.2017.12.005. PMC 5884165. PMID 29458964.
van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, et al. (August 2009). "An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis". The Lancet. Oncology. 10 (8): 764–771. doi:10.1016/S1470-2045(09)70164-0. PMC 4718191. PMID 19576851.
Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, et al. (July 2016). "Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome". The American Journal of Surgical Pathology. 40 (7): 865–875. doi:10.1097/pas.0000000000000617. hdl:2158/1116837. PMID 26900816. S2CID 205917783.
Schmidt C, Sciacovelli M, Frezza C (February 2020). "Fumarate hydratase in cancer: A multifaceted tumour suppressor". Seminars in Cell & Developmental Biology. 98: 15–25. doi:10.1016/j.semcdb.2019.05.002. PMC 6974395. PMID 31085323.
Benjamin DI, Cravatt BF, Nomura DK (November 2012). "Global profiling strategies for mapping dysregulated metabolic pathways in cancer". Cell Metabolism. 16 (5): 565–577. doi:10.1016/j.cmet.2012.09.013. PMC 3539740. PMID 23063552.
Chaudhri VK, Salzler GG, Dick SA, Buckman MS, Sordella R, Karoly ED, et al. (June 2013). "Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor". Molecular Cancer Research. 11 (6): 579–592. doi:10.1158/1541-7786.mcr-12-0437-t. PMC 3686965. PMID 23475953.
Wishart DS (June 2015). "Is Cancer a Genetic Disease or a Metabolic Disease?". eBioMedicine. 2 (6): 478–479. doi:10.1016/j.ebiom.2015.05.022. PMC 4535307. PMID 26288805.
Koo I, Wei X, Zhang X (2014). "Analysis of Metabolomic Profiling Data Acquired on GC–MS". Cell-wide Metabolic Alterations Associated with Malignancy. Methods in Enzymology. Vol. 543. Elsevier. pp. 315–324. doi:10.1016/B978-0-12-801329-8.00016-7. ISBN 9780128013298. PMID 24924140.
Liu L, Hu K, Feng J, Wang H, Fu S, Wang B, et al. (January 2021). "The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation". BMC Cancer. 21 (1): 36. doi:10.1186/s12885-020-07744-x. PMC 7791852. PMID 33413208.
Haug K, Cochrane K, Nainala VC, Williams M, Chang J, Jayaseelan KV, O'Donovan C (January 2020). "MetaboLights: a resource evolving in response to the needs of its scientific community". Nucleic Acids Research. 48 (D1): D440 – D444. doi:10.1093/nar/gkz1019. PMC 7145518. PMID 31691833.
Haug K, Salek RM, Conesa P, Hastings J, de Matos P, Rijnbeek M, et al. (January 2013). "MetaboLights--an open-access general-purpose repository for metabolomics studies and associated meta-data". Nucleic Acids Research. 41 (Database issue): D781 – D786. doi:10.1093/nar/gks1004. PMC 3531110. PMID 23109552.
Park JH, Pyun WY, Park HW (October 2020). "Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets". Cells. 9 (10): 2308. doi:10.3390/cells9102308. PMC 7602974. PMID 33081387.
Luengo A, Gui DY, Vander Heiden MG (September 2017). "Targeting Metabolism for Cancer Therapy". Cell Chemical Biology. 24 (9): 1161–1180. doi:10.1016/j.chembiol.2017.08.028. PMC 5744685. PMID 28938091.
Andrieu G, Tran AH, Strissel KJ, Denis GV (November 2016). "BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling". Cancer Research. 76 (22): 6555–6567. doi:10.1158/0008-5472.CAN-16-0559. PMC 5290198. PMID 27651315.
Jafari N, Kolla M, Meshulam T, Shafran JS, Qiu Y, Casey AN, et al. (November 2021). "Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes". Science Signaling. 14 (710): eabj2807. doi:10.1126/scisignal.abj2807. ISSN 1945-0877. PMC 8765301. PMID 34813359. S2CID 244529960.

ebi.ac.uk

"MetaboLights - Metabolomics experiments and derived information". www.ebi.ac.uk. Retrieved 2021-11-08.

handle.net

hdl.handle.net

Lunt SY, Vander Heiden MG (2011-11-10). "Aerobic glycolysis: meeting the metabolic requirements of cell proliferation". Annual Review of Cell and Developmental Biology. 27 (1): 441–464. doi:10.1146/annurev-cellbio-092910-154237. hdl:1721.1/78654. PMID 21985671.
Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, et al. (July 2016). "Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome". The American Journal of Surgical Pathology. 40 (7): 865–875. doi:10.1097/pas.0000000000000617. hdl:2158/1116837. PMID 26900816. S2CID 205917783.

harvard.edu

ui.adsabs.harvard.edu

DeBerardinis RJ, Chandel NS (May 2016). "Fundamentals of cancer metabolism". Science Advances. 2 (5): e1600200. Bibcode:2016SciA....2E0200D. doi:10.1126/sciadv.1600200. PMC 4928883. PMID 27386546.
Chen M, Yang MH, Chang MM, Tyan YC, Chen YA (September 2019). "Tumor suppressor gene glycine N-methyltransferase and its potential in liver disorders and hepatocellular carcinoma". Toxicology and Applied Pharmacology. 378: 114607. Bibcode:2019ToxAP.37814607C. doi:10.1016/j.taap.2019.114607. PMID 31170416. S2CID 174817577.
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. (February 2012). "IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype". Nature. 483 (7390): 479–483. Bibcode:2012Natur.483..479T. doi:10.1038/nature10866. PMC 3351699. PMID 22343889.
Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. (May 2013). "Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation". Science. 340 (6132): 622–626. Bibcode:2013Sci...340..622W. doi:10.1126/science.1234769. PMID 23558173. S2CID 9292787.

nih.gov

pubmed.ncbi.nlm.nih.gov

Urbano AM (January 2021). "Otto Warburg: The journey towards the seminal discovery of tumor cell bioenergetic reprogramming". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1867 (1): 165965. doi:10.1016/j.bbadis.2020.165965. PMID 32949769. S2CID 221807074.
Oliveira PJ, Urbano AM (February 2021). ""Oncometabolism: The switchboard of cancer - An editorial"". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1867 (2): 166031. doi:10.1016/j.bbadis.2020.166031. PMID 33310398. S2CID 229175329.
Dando I, Pozza ED, Ambrosini G, Torrens-Mas M, Butera G, Mullappilly N, et al. (August 2019). "Oncometabolites in cancer aggressiveness and tumour repopulation". Biological Reviews of the Cambridge Philosophical Society. 94 (4): 1530–1546. doi:10.1111/brv.12513. PMID 30972955. S2CID 108294182.
Biswas SK (September 2015). "Metabolic Reprogramming of Immune Cells in Cancer Progression". Immunity. 43 (3): 435–449. doi:10.1016/j.immuni.2015.09.001. PMID 26377897.
Vaupel P, Schmidberger H, Mayer A (July 2019). "The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression". International Journal of Radiation Biology. 95 (7): 912–919. doi:10.1080/09553002.2019.1589653. PMID 30822194. S2CID 73502809.
Pascale RM, Calvisi DF, Simile MM, Feo CF, Feo F (September 2020). "The Warburg Effect 97 Years after Its Discovery". Cancers. 12 (10): 2819. doi:10.3390/cancers12102819. PMC 7599761. PMID 33008042.
Potter M, Newport E, Morten KJ (October 2016). "The Warburg effect: 80 years on". Biochemical Society Transactions. 44 (5): 1499–1505. doi:10.1042/bst20160094. PMC 5095922. PMID 27911732.
Lunt SY, Vander Heiden MG (2011-11-10). "Aerobic glycolysis: meeting the metabolic requirements of cell proliferation". Annual Review of Cell and Developmental Biology. 27 (1): 441–464. doi:10.1146/annurev-cellbio-092910-154237. hdl:1721.1/78654. PMID 21985671.
DeBerardinis RJ, Chandel NS (May 2016). "Fundamentals of cancer metabolism". Science Advances. 2 (5): e1600200. Bibcode:2016SciA....2E0200D. doi:10.1126/sciadv.1600200. PMC 4928883. PMID 27386546.
Wishart DS (July 2016). "Emerging applications of metabolomics in drug discovery and precision medicine". Nature Reviews. Drug Discovery. 15 (7): 473–484. doi:10.1038/nrd.2016.32. PMID 26965202. S2CID 5265996.
Gupta S, Chawla K (August 2013). "Oncometabolomics in cancer research". Expert Review of Proteomics. 10 (4): 325–336. doi:10.1586/14789450.2013.828947. PMID 23992416. S2CID 19476401.
Collins RR, Patel K, Putnam WC, Kapur P, Rakheja D (December 2017). "Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory". Clinical Chemistry. 63 (12): 1812–1820. doi:10.1373/clinchem.2016.267666. PMID 29038145.
Yang M, Soga T, Pollard PJ, Adam J (2012). "The emerging role of fumarate as an oncometabolite". Frontiers in Oncology. 2: 85. doi:10.3389/fonc.2012.00085. PMC 3408580. PMID 22866264.
Garber K (July 2010). "Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia". Journal of the National Cancer Institute. 102 (13): 926–928. doi:10.1093/jnci/djq262. PMID 20576929.
Khatami F, Aghamir SM, Tavangar SM (September 2019). "Oncometabolites: A new insight for oncology". Molecular Genetics & Genomic Medicine. 7 (9): e873. doi:10.1002/mgg3.873. PMC 6732276. PMID 31321921.
Salamanca-Cardona L, Shah H, Poot AJ, Correa FM, Di Gialleonardo V, Lui H, et al. (December 2017). "In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors". Cell Metabolism. 26 (6): 830–841.e3. doi:10.1016/j.cmet.2017.10.001. PMC 5718944. PMID 29056515.
Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, et al. (May 2013). "The role of sarcosine metabolism in prostate cancer progression". Neoplasia. 15 (5): 491–501. doi:10.1593/neo.13314. PMC 3638352. PMID 23633921.
Rodrigo MA, Strmiska V, Horackova E, Buchtelova H, Michalek P, Stiborova M, et al. (February 2018). "Sarcosine influences apoptosis and growth of prostate cells via cell-type specific regulation of distinct sets of genes". The Prostate. 78 (2): 104–112. doi:10.1002/pros.23450. PMID 29105933. S2CID 3015270.
Chen M, Yang MH, Chang MM, Tyan YC, Chen YA (September 2019). "Tumor suppressor gene glycine N-methyltransferase and its potential in liver disorders and hepatocellular carcinoma". Toxicology and Applied Pharmacology. 378: 114607. Bibcode:2019ToxAP.37814607C. doi:10.1016/j.taap.2019.114607. PMID 31170416. S2CID 174817577.
Heinzman Z, Schmidt C, Sliwinski MK, Goonesekere NC (March 2021). "The Case for GNMT as a Biomarker and a Therapeutic Target in Pancreatic Cancer". Pharmaceuticals. 14 (3): 209. doi:10.3390/ph14030209. PMC 7998508. PMID 33802396.
Chiu M, Taurino G, Bianchi MG, Kilberg MS, Bussolati O (2020-01-09). "Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia". Frontiers in Oncology. 9: 1480. doi:10.3389/fonc.2019.01480. PMC 6962308. PMID 31998641.
Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y (December 2018). "Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy". Cancer Medicine. 7 (12): 6124–6136. doi:10.1002/cam4.1820. PMC 6308051. PMID 30403008.
Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ (January 2016). "The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor". Brain Pathology. 26 (1): 3–17. doi:10.1111/bpa.12299. PMC 8029296. PMID 26269128.
Yang M, Soga T, Pollard PJ (September 2013). "Oncometabolites: linking altered metabolism with cancer". The Journal of Clinical Investigation. 123 (9): 3652–3658. doi:10.1172/jci67228. PMC 3754247. PMID 23999438.
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. (February 2012). "IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype". Nature. 483 (7390): 479–483. Bibcode:2012Natur.483..479T. doi:10.1038/nature10866. PMC 3351699. PMID 22343889.
Jones PA, Baylin SB (February 2007). "The epigenomics of cancer". Cell. 128 (4): 683–692. doi:10.1016/j.cell.2007.01.029. PMC 3894624. PMID 17320506.
Letouzé E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, et al. (June 2013). "SDH mutations establish a hypermethylator phenotype in paraganglioma". Cancer Cell. 23 (6): 739–752. doi:10.1016/j.ccr.2013.04.018. PMID 23707781.
Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. (January 2012). "2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas". Nature Medicine. 18 (4): 624–629. doi:10.1038/nm.2682. PMC 3615719. PMID 22281806.
Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. (May 2013). "Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation". Science. 340 (6132): 622–626. Bibcode:2013Sci...340..622W. doi:10.1126/science.1234769. PMID 23558173. S2CID 9292787.
Ye D, Guan KL, Xiong Y (February 2018). "Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates". Trends in Cancer. 4 (2): 151–165. doi:10.1016/j.trecan.2017.12.005. PMC 5884165. PMID 29458964.
van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, et al. (August 2009). "An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis". The Lancet. Oncology. 10 (8): 764–771. doi:10.1016/S1470-2045(09)70164-0. PMC 4718191. PMID 19576851.
Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, et al. (July 2016). "Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome". The American Journal of Surgical Pathology. 40 (7): 865–875. doi:10.1097/pas.0000000000000617. hdl:2158/1116837. PMID 26900816. S2CID 205917783.
Schmidt C, Sciacovelli M, Frezza C (February 2020). "Fumarate hydratase in cancer: A multifaceted tumour suppressor". Seminars in Cell & Developmental Biology. 98: 15–25. doi:10.1016/j.semcdb.2019.05.002. PMC 6974395. PMID 31085323.
Benjamin DI, Cravatt BF, Nomura DK (November 2012). "Global profiling strategies for mapping dysregulated metabolic pathways in cancer". Cell Metabolism. 16 (5): 565–577. doi:10.1016/j.cmet.2012.09.013. PMC 3539740. PMID 23063552.
Chaudhri VK, Salzler GG, Dick SA, Buckman MS, Sordella R, Karoly ED, et al. (June 2013). "Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor". Molecular Cancer Research. 11 (6): 579–592. doi:10.1158/1541-7786.mcr-12-0437-t. PMC 3686965. PMID 23475953.
Wishart DS (June 2015). "Is Cancer a Genetic Disease or a Metabolic Disease?". eBioMedicine. 2 (6): 478–479. doi:10.1016/j.ebiom.2015.05.022. PMC 4535307. PMID 26288805.
Koo I, Wei X, Zhang X (2014). "Analysis of Metabolomic Profiling Data Acquired on GC–MS". Cell-wide Metabolic Alterations Associated with Malignancy. Methods in Enzymology. Vol. 543. Elsevier. pp. 315–324. doi:10.1016/B978-0-12-801329-8.00016-7. ISBN 9780128013298. PMID 24924140.
Liu L, Hu K, Feng J, Wang H, Fu S, Wang B, et al. (January 2021). "The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation". BMC Cancer. 21 (1): 36. doi:10.1186/s12885-020-07744-x. PMC 7791852. PMID 33413208.
Haug K, Cochrane K, Nainala VC, Williams M, Chang J, Jayaseelan KV, O'Donovan C (January 2020). "MetaboLights: a resource evolving in response to the needs of its scientific community". Nucleic Acids Research. 48 (D1): D440 – D444. doi:10.1093/nar/gkz1019. PMC 7145518. PMID 31691833.
Haug K, Salek RM, Conesa P, Hastings J, de Matos P, Rijnbeek M, et al. (January 2013). "MetaboLights--an open-access general-purpose repository for metabolomics studies and associated meta-data". Nucleic Acids Research. 41 (Database issue): D781 – D786. doi:10.1093/nar/gks1004. PMC 3531110. PMID 23109552.
Park JH, Pyun WY, Park HW (October 2020). "Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets". Cells. 9 (10): 2308. doi:10.3390/cells9102308. PMC 7602974. PMID 33081387.
Luengo A, Gui DY, Vander Heiden MG (September 2017). "Targeting Metabolism for Cancer Therapy". Cell Chemical Biology. 24 (9): 1161–1180. doi:10.1016/j.chembiol.2017.08.028. PMC 5744685. PMID 28938091.
Andrieu G, Tran AH, Strissel KJ, Denis GV (November 2016). "BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling". Cancer Research. 76 (22): 6555–6567. doi:10.1158/0008-5472.CAN-16-0559. PMC 5290198. PMID 27651315.
Jafari N, Kolla M, Meshulam T, Shafran JS, Qiu Y, Casey AN, et al. (November 2021). "Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes". Science Signaling. 14 (710): eabj2807. doi:10.1126/scisignal.abj2807. ISSN 1945-0877. PMC 8765301. PMID 34813359. S2CID 244529960.

ncbi.nlm.nih.gov

Pascale RM, Calvisi DF, Simile MM, Feo CF, Feo F (September 2020). "The Warburg Effect 97 Years after Its Discovery". Cancers. 12 (10): 2819. doi:10.3390/cancers12102819. PMC 7599761. PMID 33008042.
Potter M, Newport E, Morten KJ (October 2016). "The Warburg effect: 80 years on". Biochemical Society Transactions. 44 (5): 1499–1505. doi:10.1042/bst20160094. PMC 5095922. PMID 27911732.
DeBerardinis RJ, Chandel NS (May 2016). "Fundamentals of cancer metabolism". Science Advances. 2 (5): e1600200. Bibcode:2016SciA....2E0200D. doi:10.1126/sciadv.1600200. PMC 4928883. PMID 27386546.
Yang M, Soga T, Pollard PJ, Adam J (2012). "The emerging role of fumarate as an oncometabolite". Frontiers in Oncology. 2: 85. doi:10.3389/fonc.2012.00085. PMC 3408580. PMID 22866264.
Khatami F, Aghamir SM, Tavangar SM (September 2019). "Oncometabolites: A new insight for oncology". Molecular Genetics & Genomic Medicine. 7 (9): e873. doi:10.1002/mgg3.873. PMC 6732276. PMID 31321921.
Salamanca-Cardona L, Shah H, Poot AJ, Correa FM, Di Gialleonardo V, Lui H, et al. (December 2017). "In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors". Cell Metabolism. 26 (6): 830–841.e3. doi:10.1016/j.cmet.2017.10.001. PMC 5718944. PMID 29056515.
Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, et al. (May 2013). "The role of sarcosine metabolism in prostate cancer progression". Neoplasia. 15 (5): 491–501. doi:10.1593/neo.13314. PMC 3638352. PMID 23633921.
Heinzman Z, Schmidt C, Sliwinski MK, Goonesekere NC (March 2021). "The Case for GNMT as a Biomarker and a Therapeutic Target in Pancreatic Cancer". Pharmaceuticals. 14 (3): 209. doi:10.3390/ph14030209. PMC 7998508. PMID 33802396.
Chiu M, Taurino G, Bianchi MG, Kilberg MS, Bussolati O (2020-01-09). "Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia". Frontiers in Oncology. 9: 1480. doi:10.3389/fonc.2019.01480. PMC 6962308. PMID 31998641.
Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y (December 2018). "Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy". Cancer Medicine. 7 (12): 6124–6136. doi:10.1002/cam4.1820. PMC 6308051. PMID 30403008.
Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ (January 2016). "The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor". Brain Pathology. 26 (1): 3–17. doi:10.1111/bpa.12299. PMC 8029296. PMID 26269128.
Yang M, Soga T, Pollard PJ (September 2013). "Oncometabolites: linking altered metabolism with cancer". The Journal of Clinical Investigation. 123 (9): 3652–3658. doi:10.1172/jci67228. PMC 3754247. PMID 23999438.
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. (February 2012). "IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype". Nature. 483 (7390): 479–483. Bibcode:2012Natur.483..479T. doi:10.1038/nature10866. PMC 3351699. PMID 22343889.
Jones PA, Baylin SB (February 2007). "The epigenomics of cancer". Cell. 128 (4): 683–692. doi:10.1016/j.cell.2007.01.029. PMC 3894624. PMID 17320506.
Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. (January 2012). "2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas". Nature Medicine. 18 (4): 624–629. doi:10.1038/nm.2682. PMC 3615719. PMID 22281806.
Ye D, Guan KL, Xiong Y (February 2018). "Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates". Trends in Cancer. 4 (2): 151–165. doi:10.1016/j.trecan.2017.12.005. PMC 5884165. PMID 29458964.
van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, et al. (August 2009). "An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis". The Lancet. Oncology. 10 (8): 764–771. doi:10.1016/S1470-2045(09)70164-0. PMC 4718191. PMID 19576851.
Schmidt C, Sciacovelli M, Frezza C (February 2020). "Fumarate hydratase in cancer: A multifaceted tumour suppressor". Seminars in Cell & Developmental Biology. 98: 15–25. doi:10.1016/j.semcdb.2019.05.002. PMC 6974395. PMID 31085323.
Benjamin DI, Cravatt BF, Nomura DK (November 2012). "Global profiling strategies for mapping dysregulated metabolic pathways in cancer". Cell Metabolism. 16 (5): 565–577. doi:10.1016/j.cmet.2012.09.013. PMC 3539740. PMID 23063552.
Chaudhri VK, Salzler GG, Dick SA, Buckman MS, Sordella R, Karoly ED, et al. (June 2013). "Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor". Molecular Cancer Research. 11 (6): 579–592. doi:10.1158/1541-7786.mcr-12-0437-t. PMC 3686965. PMID 23475953.
Wishart DS (June 2015). "Is Cancer a Genetic Disease or a Metabolic Disease?". eBioMedicine. 2 (6): 478–479. doi:10.1016/j.ebiom.2015.05.022. PMC 4535307. PMID 26288805.
Liu L, Hu K, Feng J, Wang H, Fu S, Wang B, et al. (January 2021). "The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation". BMC Cancer. 21 (1): 36. doi:10.1186/s12885-020-07744-x. PMC 7791852. PMID 33413208.
Haug K, Cochrane K, Nainala VC, Williams M, Chang J, Jayaseelan KV, O'Donovan C (January 2020). "MetaboLights: a resource evolving in response to the needs of its scientific community". Nucleic Acids Research. 48 (D1): D440 – D444. doi:10.1093/nar/gkz1019. PMC 7145518. PMID 31691833.
Haug K, Salek RM, Conesa P, Hastings J, de Matos P, Rijnbeek M, et al. (January 2013). "MetaboLights--an open-access general-purpose repository for metabolomics studies and associated meta-data". Nucleic Acids Research. 41 (Database issue): D781 – D786. doi:10.1093/nar/gks1004. PMC 3531110. PMID 23109552.
Park JH, Pyun WY, Park HW (October 2020). "Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets". Cells. 9 (10): 2308. doi:10.3390/cells9102308. PMC 7602974. PMID 33081387.
Luengo A, Gui DY, Vander Heiden MG (September 2017). "Targeting Metabolism for Cancer Therapy". Cell Chemical Biology. 24 (9): 1161–1180. doi:10.1016/j.chembiol.2017.08.028. PMC 5744685. PMID 28938091.
Andrieu G, Tran AH, Strissel KJ, Denis GV (November 2016). "BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling". Cancer Research. 76 (22): 6555–6567. doi:10.1158/0008-5472.CAN-16-0559. PMC 5290198. PMID 27651315.
Jafari N, Kolla M, Meshulam T, Shafran JS, Qiu Y, Casey AN, et al. (November 2021). "Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes". Science Signaling. 14 (710): eabj2807. doi:10.1126/scisignal.abj2807. ISSN 1945-0877. PMC 8765301. PMID 34813359. S2CID 244529960.

semanticscholar.org

api.semanticscholar.org

Urbano AM (January 2021). "Otto Warburg: The journey towards the seminal discovery of tumor cell bioenergetic reprogramming". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1867 (1): 165965. doi:10.1016/j.bbadis.2020.165965. PMID 32949769. S2CID 221807074.
Oliveira PJ, Urbano AM (February 2021). ""Oncometabolism: The switchboard of cancer - An editorial"". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1867 (2): 166031. doi:10.1016/j.bbadis.2020.166031. PMID 33310398. S2CID 229175329.
Dando I, Pozza ED, Ambrosini G, Torrens-Mas M, Butera G, Mullappilly N, et al. (August 2019). "Oncometabolites in cancer aggressiveness and tumour repopulation". Biological Reviews of the Cambridge Philosophical Society. 94 (4): 1530–1546. doi:10.1111/brv.12513. PMID 30972955. S2CID 108294182.
Vaupel P, Schmidberger H, Mayer A (July 2019). "The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression". International Journal of Radiation Biology. 95 (7): 912–919. doi:10.1080/09553002.2019.1589653. PMID 30822194. S2CID 73502809.
Wishart DS (July 2016). "Emerging applications of metabolomics in drug discovery and precision medicine". Nature Reviews. Drug Discovery. 15 (7): 473–484. doi:10.1038/nrd.2016.32. PMID 26965202. S2CID 5265996.
Gupta S, Chawla K (August 2013). "Oncometabolomics in cancer research". Expert Review of Proteomics. 10 (4): 325–336. doi:10.1586/14789450.2013.828947. PMID 23992416. S2CID 19476401.
Rodrigo MA, Strmiska V, Horackova E, Buchtelova H, Michalek P, Stiborova M, et al. (February 2018). "Sarcosine influences apoptosis and growth of prostate cells via cell-type specific regulation of distinct sets of genes". The Prostate. 78 (2): 104–112. doi:10.1002/pros.23450. PMID 29105933. S2CID 3015270.
Chen M, Yang MH, Chang MM, Tyan YC, Chen YA (September 2019). "Tumor suppressor gene glycine N-methyltransferase and its potential in liver disorders and hepatocellular carcinoma". Toxicology and Applied Pharmacology. 378: 114607. Bibcode:2019ToxAP.37814607C. doi:10.1016/j.taap.2019.114607. PMID 31170416. S2CID 174817577.
Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. (May 2013). "Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation". Science. 340 (6132): 622–626. Bibcode:2013Sci...340..622W. doi:10.1126/science.1234769. PMID 23558173. S2CID 9292787.
Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, et al. (July 2016). "Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome". The American Journal of Surgical Pathology. 40 (7): 865–875. doi:10.1097/pas.0000000000000617. hdl:2158/1116837. PMID 26900816. S2CID 205917783.
Jafari N, Kolla M, Meshulam T, Shafran JS, Qiu Y, Casey AN, et al. (November 2021). "Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes". Science Signaling. 14 (710): eabj2807. doi:10.1126/scisignal.abj2807. ISSN 1945-0877. PMC 8765301. PMID 34813359. S2CID 244529960.

worldcat.org

search.worldcat.org

Jafari N, Kolla M, Meshulam T, Shafran JS, Qiu Y, Casey AN, et al. (November 2021). "Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes". Science Signaling. 14 (710): eabj2807. doi:10.1126/scisignal.abj2807. ISSN 1945-0877. PMC 8765301. PMID 34813359. S2CID 244529960.